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Abstract
Rationale—SWI/SNF chromatin-remodeling complexes utilize either BRG1 or BRM as a
catalytic subunit to alter nucleosome position and regulate gene expression. BRG1 is required for
vascular endothelial cell (VEC) development and embryonic survival, whereas BRM is
dispensable.
Objective—To circumvent embryonic lethality and study Brg1 function in adult tissues, we
utilized conditional gene targeting. To evaluate possible Brg1-Brm redundancy, we analyzed Brg1
mutant mice on wild-type and Brm-deficient backgrounds.
Methods and Results—The inducible Mx1-Cre driver was used to mutate Brg1 in adult mice.
These conditional-null mutants exhibited a tissue-specific phenotype and unanticipated functional
compensation between Brg1 and Brm. Brg1 single mutants were healthy and had a normal
lifespan, whereas Brg1/Brm double mutants exhibited cardiovascular defects and died within one
month. BRG1 and BRM were required for the viability of VECs but not other cell types where
both genes were also knocked out. The VEC phenotype was most evident in the heart, particularly
in the microvasculature of the outer myocardium, and was recapitulated in primary cells ex vivo.
VEC death resulted in vascular leakage, cardiac hemorrhage, secondary death of cardiomyocytes
due to ischemia, and ventricular dissections.
Conclusions—BRG1-catalyzed SWI/SNF complexes are particularly important in
cardiovascular tissues. However, in contrast to embryonic development, where Brm does not
compensate, Brg1 is required in adult VECs only when Brm is also mutated. These results
demonstrate for the first time that Brm functionally compensates for Brg1 in vivo and that there
are significant changes in the relative importance of BRG1- and BRM-catalyzed SWI/SNF
complexes during the development of an essential cell lineage.
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Introduction
The Saccharomyces cerevisiae SWI/SNF (mating type switching/sucrose non-fermenting)
complex was the first chromatin-remodeling complex to be characterized and consists of 11
subunits with a total molecular mass of 1-2 MDa.1,2 SWI/SNF complexes have been
evolutionarily conserved although mammals have approximately 21 subunits due to
duplication and divergence events that occurred during vertebrate evolution.3 Rather than
having a larger-sized complex consisting of 21 subunits, mammals have a number of 9-12
subunit complexes with different combinatorial assemblies (up to n=288 in theory).3,4
Subunit composition can change within a cell lineage as it differentiates and is known to
vary among different tissues.4,5 However, despite this subunit diversity, all mammalian
SWI/SNF complexes identified thus far contain either BRG1 or BRM (brahma-related gene
1 and brahma, also known as SMARCA4 and SMARCA2, respectively) as a catalytic
subunit with DNA-dependent ATPase activity.3,4 Each complex also contains several core
subunits (also known as BRG1/BRM-associated factors or BAFs) including BAF170,
BAF155, and BAF47 (also known as SNF5 or SMARCB1).3,4
SWI/SNF-related complexes are recruited by sequence-specific transcription factors to the
promoters of numerous target genes6-8, where they slide or evict histone octamers in an
ATP-dependent manner.9,10 This alters the number and position of nucleosomes near
transcriptional start sites (TSS) to regulate RNA Polymerase II occupancy and
transcriptional initiation.10-12 The importance of SWI/SNF complexes in mammalian
development has been demonstrated by mouse knockout studies. Null mutations of Brg1,
Baf250a/Arid1a, Baf155, and Baf47/Snf5 each confer peri-implantation lethality. 4,13 This
phenotype is consistent with the OCT4, SOX2, and Nanog pluripotency transcription factors
recruiting a specific SWI/SNF subcomplex, called esBAF, to target genes in embryonic stem
(ES) cells to facilitate their self-renewal and pluripotency. 7,14-16 Null mutations of the
Baf180 and Baf60c non-core subunits each result in mid-gestation lethality due to cardiac
defects. 17,18 Baf250a/Arid1a null heterozygotes and Brg1 conditional mutants also exhibit
cardiovascular defects that are lethal at midgestation. 19-21. At a mechanistic level, Brg1
genetically interacts with Tbx521, and the BAF60c subunit facilitates a physical interaction
between BRG1 and the cardiogenic transcription factors TBX5, GATA4, and Nkx2-5.17
Furthermore, a combination of BAF60c plus TBX5 and GATA4 can program non-cardiac
mesoderm into cardiomyocytes.22,23 Based on these studies, SWI/SNF complexes have
emerged as key epigenetic regulators of cardiomyocyte development.22
Cardiomyocyte development is coordinated with vascular development, and Brg1 is also
required for vasculogenesis based on the mid-gestation lethality of Brg1Tie2-Cre conditional
mutants where Brg1 was mutated in vascular endothelial cells (VECs) during
embryogenesis.24-26 The Brg1Tie2-Cre mutant phenotype was not exacerbated by Brm
deficiency25, which is surprising because Brm is expressed at high levels in the developing
vasculature and encodes a protein that is 75% identical to BRG1 with similar or identical
chromatin-remodeling properties on nucleosome arrays in cell-free systems.27,28 This
finding suggests that VECs may rely on the PBAF class of complexes, which utilize only
BRG1 as their catalytic subunit, rather than the BAF class that utilizes either BRG1 or
BRM.3 This possibility has a precedent as the esBAF subcomplex utilizes BRG1 exclusively
as a catalytic subunit. 7,14 Alternatively, BRG1 vascular function may occur in the context
of BAF complexes, but BRM cannot compensate either because it interacts with different
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transcription factors and is recruited to different target genes or it has different biochemical
properties than BRG1 in vivo.8 Support for this possibility comes from the observation that
the two catalytic subunits have antagonistic roles in the differentiation of certain cell
lineages.29 Regardless of which possibility proves correct, BRG1 and BRM clearly have
distinct functions. In fact, the function of BRM is different than all other SWI/SNF subunits
that have been knocked out thus far because Brm-/- mice are viable and fertile instead of
being embryonic lethal.4,13,30
Although BRG1-catalyzed SWI/SNF complexes are essential for cardiovascular
development and other aspects of embryogenesis4,13, it is not known whether they maintain
cellular homeostasis after development is complete. To address this important issue, it was
necessary to circumvent the requirement for Brg1 during embryogenesis so we used the
inducible Mx1-Cre driver to mutate Brg1 in several tissues of adult Brg1fl/fl mice. By
analyzing these conditional mutants on both wild-type and Brm-deficient backgrounds, we
discovered an unprecedented genetic interaction between Brg1 and Brm in cardiovascular
homeostasis as described below.
Methods
An expanded Methods section is available in the Online Data Supplement at http://
circres.ahajournals.org.
All mouse experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) review board at the University of North Carolina and were performed in
accordance with federal guidelines. The Brg1 floxed and Δfloxed alleles and the Brm
mutation were genotyped by PCR as previously described.30,31 To induce Mx1-Cre in vivo,
mice were injected intraperitoneally with 300 mg of pI-pC (Sigma, St Louis, MO, USA)
dissolved in PBS in a volume of 0.2 cc. Mice were injected every other day for a total of 5
treatments. Control mice received the same injection regimen but with PBS only.
Histology was performed by fixing heart and other tissues in 4% paraformaldehyde,
embedding in paraffin, and cutting 5-μm sections according to standard procedures.
Sections were either stained with H&E or processed for IHC using a BRG1 rabbit
polyclonal antibody (Upstate/Millipore #07-478, Temecula, CA, USA) or a PECAM-1
antibody (Upstate/Millipore #04-1074, Temecula, CA, USA) according to the
manufacturer’s recommendations. X-Gal staining was performed using standard procedures
on 200-μm vibratome slices of heart and other tissues from Rosa26 reporter (R26R, Rosa-
lox-stop-lox-LacZ) mice carrying the Mx1-Cre transgene.
For electron microscopy, following perfusion with 2% paraformaldehyde and 2.5%
glutaraldehyde in 0.15 M sodium phosphate buffer (pH 7.4), heart and other tissues were
fixed in the same solution overnight and then post-fixed with 1% osmium tetroxide/0.15M
sodium phosphate buffer. Samples were dehydrated with increasing concentrations of
ethanol, infiltrated and embedded in Polybed 812 epoxy resin (Polysciences, Warrington,
PA, USA), and 70-nm ultrathin sections were cut with a diamond knife. Sections were
mounted on 200-mesh copper grids and staining with 4% aqueous uranyl acetate and
Reynolds’ lead citrate. Sections were observed with a LEO EM910 transmission electron
microscope operating at 80 kV (LEO Electron Microscopy, Thornwood, NY, USA) and
photographed with a Gatan-Orius SC1000 CCD Digital Camera and Digital Micrograph
3.11.0 (Gatan, Pleasanton, CA, USA).
Primary VECs were isolated and cultured as described with minor modifications.32 Mouse
hearts were minced and digested with collagenase solution [0.2 mg/mL type II collagenase
(Worthington, Lakewood, NJ, USA) in Hank’s Balanced Salt solution (Biowhittaker/Lonza,
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Basel, Switzerland)] for 45 min at 37°C to generate single-cell suspensions. Cells were
filtered through cell strainers and washed in base media (DMEM containing 25-mM
HEPES, 20% FBS, 100U/100mg/mL penicillin-streptomyocin, and 2-mM glutamine). The
samples were incubated with a biotinylated PECAM-1 antibody (BD Pharmingen, San
Diego, CA, USA) for 10 min. Streptavidin-coated magnetic beads (Miltenyi Biotech,
Auburn, CA, USA) were then added to the samples and incubated for 15 min at 4°C while
rotating. The immunobead complex was then isolated by passing the samples through
magnetic columns (Miltenyi Biotech), washing 3 times, and resuspending in complete
culture media [basal media plus 100 mg/mL heparin (Sigma), 100 mg/mL endothelial cell
growth stimulant (Biomedical Technologies, Stoughton, MA, USA), and sodium pyruvate
(Invitrogen, Carlsbad, CA, USA)]. Cells were grown in 10-cm culture dishes pretreated with
0.1% gelatin in complete culture media under standard conditions (5% CO2 at 37°C), and
cultures were re-fed every other day and could be passaged several times while retaining
their morphological appearance and PECAM-1-positive status. To induce Cre expression
and mutate Brg1, pI-pC (Sigma) was added to VEC cultures at a final concentration of 100
μg/mL for 3 successive days.
Trans-thoracic echocardiography was performed on conscious mice using a VisualSonics
Vevo 770 ultrasound biomicroscopy system (VisualSonics, Inc., Toronton, Ontario) with a
30-MHz 707B scan head as previously described.33-35 Two-dimensional guided M-mode
analysis of the left ventricle was performed in a genotype-blinded fashion in the plane of the
parasternal long-axis at the level of the papillary muscle. Epi- and endo- cardium leading
edges were used to the measure the anterior and posterior wall thickness (IVSTD, IVSTS),
posterior wall thickness (PWTD, PWTS), and left ventricular internal diameters (LVEDD,
LVESD). LV volume in diastole (LV VolD) was calculated from the equation LV VolD =
(7/2.4 + LVEDD) × LVEDD3 × 1000, and LV volume in systole (LV VolS) was calculated
from the equation LV VolS = (7/2.4 + LVESD) × LVESD3 × 1000. Left ventricular systolic
function was assessed by ejection fraction (EF), calculated from the equation EF % = (LV
VolD-LV VolS)/LV VolD × 100, and fractional shortening (FS), calculated from the
equation FS % = (LVEDD-LVESD)/LVEDD × 100. M-mode measurements represent 3
average consecutive cardiac cycles from each mouse.
Results
Functional Compensation of Brg1 and Brm
To investigate the role of Brg1 in adult tissues, we crossed previously characterized Mx1-
Cre transgenic mice and Brg1 floxed mice to generate Brg1 conditional null homozygotes
(Brg1fl/fl; Mx1-Cre+/0). 31,36 Because Mx1-Cre is inducible, Cre is not expressed and the
floxed-to-Δfloxed excision does not occur until after the mice have been injected with
polyinosinic-polycytidylic acid (pI-pC), a synthetic double-stranded RNA that activates the
interferon-responsive Mx1 promoter.36 Previous studies of Mx1-Cre using Rosa26 reporter
(R26R) mice have demonstrated that pI-pC treatment results in Cre-mediated excision in the
following cell types: hematopoietic stem cells and their descendants, hepatocytes, VECs
throughout the body, the gastric epithelium, kidney (collecting ducts, glomeruli, and renal
vascular endothelium), and smooth muscle in a subset of organs. 36,37 Therefore, each of
these cell types will be functionally null in our Brg1 conditional null homozygotes following
pI-pC treatment. To assess excision of the Brg1 locus, we performed PCR on tissues from
Brg1fl/fl; Mx1-Cre+/0 mice. We detected the Brg1 Δfloxed PCR product in mice that were
treated with pI-pC but not in control mice that were treated with vehicle (PBS) or that were
untreated (Figure 1A). These results confirmed that the Brg1 excision event was induced by
pI-pC as expected.
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We administered either pI-pC or PBS to three categories of mice at 5-7 weeks of age and
monitored their health and survival. The first category consisted of 40 control mice divided
into four subcategories: 1, Brg1fl/fl mice lacking the Mx1-Cre transgene that were treated
with pI-pC (n = 10); 2, Brg1fl/fl mice lacking the Mx1-Cre transgene on a Brm-/- background
that were treated with pI-pC (n = 10); 3, Brg1 conditional null homozygotes (Brg1fl/fl; Mx1-
Cre+/0) that were treated with PBS (n = 10); 4, Brg1 conditional null homozygotes on a
Brm-/- background that were treated with PBS (n = 10). Brg1 was not mutated in any of
these control mice, and each animal was healthy and had normal survival as expected
(Figure 1B). The second category was comprised of 25 single mutants: Brg1 conditional null
homozygotes on a wild-type (n = 15) or Brm+/- (n = 10) background that were treated with
pI-pC (herein referred to as Brg1Mx1-Cre single mutants). All of these animals were also
healthy and had normal survival (Figure 1B) and a normal lifespan (26 ± 5 months). The
third category was double mutants: Brg1 conditional null homozygotes on a Brm-/-
background that were treated with pI-pC (n = 15). These mice (herein referred to as
Brg1Mx1-Cre/Brm-/- double mutants) either died or had to be euthanized within one month of
pI-pC treatment due to their moribund condition (e.g. hunched posture, lethargy, labored
breathing, and reduced response to direct contact) (Figure 1B). This phenotype was 100%
penetrant as all 15 Brg1Mx-Cre/Brm-/- double mutants became moribund. These results
indicate that the Brg1 and Brm catalytic subunits functionally compensate in the Mx1-Cre
model.
Brg1Mx1-Cre/Brm-/- Double-Mutant Mice Exhibit Cardiac Defects and Ventricular Dissections
To begin to understand the cause of death, Brg1Mx1-Cre/Brm-/- double mutant mice were
euthanized 20-30 days after pI-pC treatment, while they were moribund. Pleural effusions
were present in nearly all mice, characteristically being a clear to blood-tinged fluid. Gross
examination of these mice also revealed a kidney phenotype consistent with medullary
congestion (Online Figure 1A). Other organ systems including the liver and gastrointestinal
tract, were grossly unremarkable and indistinguishable from control mice.
Since pleural effusions can be associated with cardiac defects such as heart failure, we first
analyzed the hearts and lungs from Brg1Mx1-Cre/Brm-/- double mutants that had been treated
20-30 days earlier with pI-pC. Unlike control hearts (Figure 2A), numerous extravascular
erythrocytes were identified within the myocardial interstitium of the atria and throughout
the left and right ventricular myocardium from the apex to the base of double-mutant hearts
(Figure 2B). This hemorrhage was particularly evident in the outer myocardium
(representative sections shown in Figure 2B), while the endocardium and valve endothelium
appeared normal at this level of magnification. Whereas the structural integrity of the aortic
root, pulmonary artery, and coronary arteries remained intact (data not shown), we observed
the subepicardial microvasculature as the primary source of the multifocal hemorrhages into
the interstitium (Figure 2B). Brg1Mx1-Cre/Brm-/- double-mutant hearts also exhibited areas
of necrotic cardiomyocytes, a subset of which showed dystrophic calcification, scattered
diffusely throughout the hemorrhagic myocardium (Figure 2B and Online Figure II), and
this was associated with myocardial dissections identified by 2D echocardiography (Figure
2C). There were acute and chronic inflammatory cells within the affected myocardium, as
well as reactive fibroblasts in areas with chronic cardiomyocyte injury (data not shown).
Based on the analysis of Masson’s Trichrome stained sections, Brg1Mx1-Cre/Brm-/- double-
mutant hearts also had significant fibrosis (Online Figure II) and cardiomyocyte hypertrophy
(Online Figure IIIA). Quantification of cardiomyocyte cross-sectional areas revealed a 1.6-
fold increase in double mutants compared to controls (Online Figure IIIB). In contrast to the
heart, we did not detect any histopathologic abnormalities or abnormal cell death in the
lungs or kidneys from Brg1Mx1-Cre/Brm-/- double-mutant mice (Online Figure I).
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To more carefully define the cardiac phenotype and provide insight into the kinetics of
disease progression, we conducted a longitudinal echocardiographic study. Following pI-pC
treatment, we performed daily trans-thoracic echocardiography on 9 conscious Brg1Mx1-Cre/
Brm-/- double mutants until each animal died or was euthanized due to humane endpoints.
We also longitudinally analyzed 6 sibling-matched controls: 3 Brg1Mx1-Cre/Brm-/- double
mutants that were not treated with pI-pC, and 3 Brg1fl/fl, Brm-/- mice lacking the Mx1-Cre
transgene that were treated with pI-pC. On the first day of echocardiography (on the day
after the final pI-pC treatment corresponding to day 9 in Figure 1B), we did not detect any
significant differences for 15 quantitative measurements, referred to as “baseline”, between
the treated double mutants and the two control groups (Figure 3A, Table 1). On subsequent
echocardiographic studies, we detected an increased thickness of the anterior or posterior
left ventricular wall of treated double mutants between 7 and 21 days later (median of 14
days) (Online Figure IV and Online Table I). In contrast, ventricular wall measurements did
not change over time in any of the control mice (Online Figure IV). The left ventricular wall
of the treated Brg1Mx1-Cre/Brm-/- double mutant mice became progressively thicker over
time (Online Figure IV). On the final echocardiogram, acquired one day before their death
[(i.e., pre-mortem) median of 25 days following first echocardiogram (Online Table I) or 34
days following their first pI-pC treatment], the left ventricular wall of the Brg1Mx1-Cre/
Brm-/- double mutant mice was nearly twice that of controls (Figure 3A, Table 1). For
example, the anterior wall thickness in diastole was 1.84 +/- 0.11 mm in treated double
mutants compared to 1.04 +/- 0.04 mm and 1.06 +/- 0.02 mm in the two control groups
(Figure 3A, Table 1). In addition to increased ventricular wall thickness, treated double
mutants had a significant 2.4-fold increase in their left ventricular mass/body weight ratio
and a 42% decrease in heart rate the day before their death (Figure 3A, Table 1).
In addition to the changes identified in wall thickness, a number of additional progressive
cardiac defects were seen in the Brg1Mx1-Cre/Brm-/- double mutants. We consistently
observed pericardial and intracardiac fluid accumulation in both 2D and M-mode
echocardiography (Figure 3B). The intracardiac fluid was associated with dissections of the
anterior or posterior ventricular wall (Online Movies). We observed dissections in 56% of
the treated double mutants, and they preceded death by 3-7 days with a median of 5 days
(Online Table I). In addition, posterior wall stunning was identified in one treated Brg1fl/fl,
Brm-/- double mutant (Online Figure V and Online Movies).
Cardiac Vascular Endothelial Cell Death is the Primary Defect
To identify the primary cellular defect in the heart of Brg1Mx1-Cre/Brm-/- double mutants, it
was necessary to determine where BRG1 is normally expressed in the heart and where Mx1-
Cre inactivates the floxed allele. Therefore, we performed immunohistochemistry (IHC) and
discovered that BRG1 is normally expressed in both VECs and cardiomyocytes throughout
the heart in a nuclear distribution (Figure 4A). Because Mx1-Cre activity has not been
characterized in the heart, we crossed the Mx1-Cre transgene onto the R26R background
and performed X-Gal staining on heart sections from these mice. Strong nuclear Cre activity
was induced by pI-pC in VECs throughout the heart but not in the cardiomyocytes (Figure
4B). No Cre activity was detected in either cell type in control mice that either lacked the
Mx1-Cre transgene or that were not treated with pI-pC as expected (Figure 4C). Therefore,
although BRG1 is expressed in both VECs and cardiomyocytes within the heart, it is only
mutated in VECs suggesting this is the primary cell type responsible for the cardiovascular
phenotype in double mutants.
We first investigated cardiac vascular endothelial cells by IHC using PECAM-1 (platelet
endothelial cell adhesion molecule, also known as CD31). A strong, continuous staining in
vessels was identified in control mice (Figure 4D). In contrast, the cardiac vasculature of
Brg1Mx1-Cre/Brm-/- double mutants had a discontinuous staining in moribund mice at 20-30
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days post-pI-pC administration (Figure 4E). This result suggested that a subset of
endothelial cells within double-mutant hearts either no longer expressed PECAM-1, or were
dead/absent. To distinguish between these possibilities, we performed transmission electron
microscopy (TEM) at 25 days post pI-pC treatment. Two distinct phenotypes were seen in
these cells. The first distinguishing phenotype of the pI-pC-treated double mutants was the
presence of dying endothelial cells attached to live VECs in the capillaries (Figure 5A).
Notably, the gap junctions were intact between the dying and live VECs (Figures 5A and B),
as they were between live cells throughout the treated Brg1Mx1-Cre/Brm-/- mutants and
control mice. The second distinguishing feature of the pI-pC-treated double mutants is that
they had variably thicker VECs with larger vesicles, compared to controls, including
swollen mitochondria and rough endoplasmic reticulum (Figure 5C). Consistent with the
histopathology seen in Figure 2, capillaries with breached endothelium were identified in
areas of hemorrhage and clot (data not shown). Many of these microvascular remnants had
immune cell infiltration, platelets, and proteinaceous material consistent with fibrin clot
formation. As expected, there was a correlation between the presence of injured and necrotic
cardiomyocytes and sites of hemorrhage.
Consistent with VECs being the primary cell type affected, it was the cell type where we
first observed a cardiac phenotype in Brg1Mx1-Cre/Brm-/- double mutants at earlier time-
points following the induction of the Brg1 mutation. For example, when we analyzed
Brg1Mx1-Cre/Brm-/- double mutants fourteen days after the first dose of pI-pC, while they
still appeared healthy and before any hemorrhage could be detected in H&E-stained
sections, the cardiomyocytes appeared normal, whereas the VECs were uniformly thickened
with increased vacuolization (Figure 6B-6D) compared to VECs found in control mice
(Figure 6A). At this 14-day post-pI-pC time point, however, we did not identify any
endothelial cells that were necrotic or absent. This phenotype was consistent with the
thickened endothelial cells seen at the later time point (days 20-30) shown in Figure 5A and
5B. Since we were unable to identify any necrotic or missing endothelial cells at day 14, but
found them readily at days 20-30, this supports a model where mutation of Brg1 and Brm in
the VEC is the primary event, which leads to VECs undergoing physical changes at or
before day 14 and VEC cell death by day 25. The distinct cardiac phenotype appears to be a
secondary consequence of this localized VEC death resulting in intramyocardial
hemorrhage, ischemia, cardiomyocyte death, and cardiac dissection.
To evaluate VEC survival/lethality in more detail, we used PECAM-1 magnetic bead sorting
to isolate and culture primary VECs from the hearts of conditional mutant and control mice.
These primary VECs had a characteristic cobblestone appearance and were PECAM-1-
positive ex vivo, and their identity was confirmed by RT-PCR since they were positive for
the VEC markers VE-cadherin and FLK1/VEGFR2 (Online Figure VI). These same cells
were negative for alpha smooth muscle actin and FLT4/VEGFR3, which are pericyte and
lymphatic endothelial cell markers, respectively (Online Figure VI). Cultures were
established from Brg1fl/fl; Mx1-Cre+/0 mice on a Brm-/- background and non-transgenic
controls (Brg1fl/fl mice lacking the Mx1-Cre transgene on a Brm-/- background). However,
none of the mice used in these experiments were treated with pI-pC so the VECs were
functional for Brg1 at the time of their derivation. Cells were then treated with pI-pC for 3
successive days, and cell number was monitored over a two-week period. Relative to day 0
(immediately prior to the first pI-pC treatment), the number of VECs from Brg1fl/fl; Mx1-
Cre+/0; Brm-/- mice (double mutants) dropped to 70% at day 7 and then to 10% at day 14
(Figure 7A). In contrast, VECs from the same mice that were not treated with pI-pC ex vivo
survived and proliferated increasing to 180% and 350% at days 7 and 14, respectively
(Figure 7A). When a BRG1 cDNA expression vector was introduced into these cells, it
rescued the drop in cell number following pI-pC-induced deletion of the endogenous Brg1
locus (Figure 7A). As a final control, the number of VECs from non-transgenic control mice
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increased to a similar extent regardless of whether or not they were treated with pI-pC as
expected (Figure 7A). These results demonstrate that the VEC phenotype is cell autonomous
and occurs under normoxic conditions.
Following pI-pC treatment, the observed decrease in the number of double-mutant cells
could be due to decreased cell proliferation and/or increased cell death. To distinguish
between these possibilities, we performed BrdU incorporation, Annexin V, and propidium
iodide assays. We did not observe a significant difference between double mutants and non-
transgenic controls for BrdU incorporation (Figure 7B) but did observe a significant
difference for Annexin V and PI staining (Figure 7B). These findings indicate that the drop
in cell number ex vivo arises because of increased apoptosis and cell death rather than
decreased cell proliferation, and this is consistent with the cell death observed in vivo. Also
similar to the in vivo phenotype, the cell death that occurred ex vivo resulted in permeability
defects based on permeability assays that measured the movement of FITC-dextran
macromolecules through a monolayer of VECs cultured on transwell inserts. The barrier
function of double-mutant cells was intact 1 day after pI-pC treatment but was compromised
7 days after pI-pC treatment (Figure 7C). To determine whether this phenotype is associated
with a perturbation in canonical SWI/SNF function, we analyzed the expression of genes
that are expressed in endothelial cells and are regulated by BRG1-catalyzed SWI/SNF-
related complexes. Accordingly, RT-qPCR showed a significant decrease in the mRNA
levels of Cd44 and Pitx2 in double-mutant cells. For this and the other assays, the
phenotypes observed in Brg1fl/fl; Mx1-Cre+/0; Brm-/- primary VECs were dependent on pI-
pC treatment as expected (Figure 7A-D).
Consequences of Vascular Permeability Defects
The occurrence of vascular permeability defects in Brg1Mx1-Cre/Brm-/- mutants might be
expected to result in increased platelet activation and clot formation. Indeed, ELISA assays
demonstrated that plasma samples from Brg1Mx1-Cre/Brm-/- mutant mice 30 days after their
first pI-pC treatment had elevated levels of platelet activation factor (PAF) and thrombin
compared to controls (Online Figure VIIA-B). Platelets isolated from the double-mutant
mice were less reactive to collagen in aggregation assays (Online Figure VIID), which is
consistent with a previous exposure to collagen as a result of compromised vessels. Platelets
are consumed during the clotting process so thrombocytopenia might also be expected, and
complete blood counts showed that Brg1Mx1-Cre/Brm-/- mutant mice had lower numbers of
platelets 30 days after the first pI-pC treatment compared to controls (Online Figure VIIE).
Finally, one might also expect VEGF levels to be increased in an attempt to compensate for
the loss of VECs, and ELISA assays demonstrated that this was the case (Online Figure
VIIC). Taken together, these secondary effects are consistent with severe vascular
permeability defects.
Discussion
Because SWI/SNF complexes are essential for embryonic development, we do not know
whether they are required for cellular homeostasis in adults. To address this issue, we
utilized the inducible Mx1-Cre driver to mutate the Brg1 catalytic subunit in various tissues
of adult mice. These conditional mutants exhibited extensive cell death in cardiac tissue but
not in other cell types that were also mutated such as the hematopoietic lineages and
hepatocytes. The tissue specificity of this cardiovascular phenotype is consistent with
previous studies demonstrating that BRG1-catalyzed SWI/SNF complexes play a
particularly important role in cardiovascular development in utero17-21,24-26, but there is an
important difference regarding redundancy. Previous studies have shown that BRM does not
compensate for BRG1 in either cardiomyocytes or VECs during embryonic
development20,21,25, whereas our data clearly demonstrate that BRM does compensate in
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VECs of adults. This difference suggests that only BRG1-catalyzed complexes function in
the establishment of VEC lineages during embryogenesis, whereas both BRG1- and BRM-
catalyzed complexes function in the maintenance of differentiated VECs in the adult.
The Mx1-Cre driver mutated Brg1 in VECs within the heart but not in cardiomyocytes.
Consequently, VEC death was the primary defect, which resulted in vascular leakage,
hemorrhage, ischemia, and cardiomyocyte death as a secondary effect. The VEC phenotype
was most evident in the microvasculature, which is relatively fragile because it lacks the
structural support that larger vessels receive from surrounding smooth muscle and
adventitia. Furthermore, the hemorrhages were almost entirely confined to the heart,
somewhat favoring the epicardium more than the endocardium, despite the fact that the
Mx1-Cre driver targets VECs throughout the body. This organ and regional specificity may
be attributed to the cardiac microvasculature being exposed to the physical forces associated
with heartbeat compared to other organs. In support of this idea, we observed
ultramicroscopic changes in double-mutant tongues, which are also subjected to physical
forces in rodents due to their licking and grooming behavior (Online Figure VIII). Notably,
the double mutants had a marked increase in the number and size of veisculo-vacuolar
organelles, which are associated with enhanced endothelial cell permeability (Online Figure
VIII)41. We would expect to observe hemorrhages in other organs if the double mutants did
not succumb to their cardiovascular defects and survived longer.
Vascular dissections have been studied most prominently in the aorta. When vascular
dissections extend into the heart itself, there is a characteristic decrease in contractility, as
seen in the present study. Recent studies have shown that an underlying cause of vascular
dissections is the induction of apoptosis of smooth muscle cells in the aortic artery, which
leads to the degradation of the media.42 Recent clinical and basic research demonstrates that
there is an inflammatory component to these dissections, which may initiate apoptosis.43
The present study links endothelial cell death with cardiac dissections, which are generally
extensions of aortic root dissections in humans. To our knowledge, Brg1 and Brm are the
first genes shown to protect against cardiac dissections. The cardiac VEC death observed in
vivo was recapitulated in primary cells ex vivo. This finding demonstrates that VEC death
due to loss of Brg1/Brm is cell autonomous and occurs under normoxic conditions (i.e.,
VEC death was not secondary to vascular leakage and ischemia).
In a previous study, we demonstrated that Brg1+/- mice developed mammary tumors, while
Brg1+/-, Brm-/- mice developed mammary and VEC (i.e., hemangiosarcoma) tumors.44 This
difference in tumor spectrum suggests that BRG1/BRM redundancy affects VEC
homeostasis with respect to tumorigenesis in addition to cell viability. The finding that
BRG1/BRM redundancy protects against oncogenic transformation instead of cell death in
these mice is likely due to BRG1 dosage (+/- versus -/-) and the accumulation of mutations
in other genes that protect against cell death. Because mutations of genes encoding SWI/
SNF subunits are common in certain types of human primary tumors45, it will be interesting
to evaluate BRG1 and BRM for point mutations when human hemangiosarcomas undergo
deep sequencing.
Finally, a negative result from this study has important mechanistic implications.
Snf5Mx1-Cre mutants exhibit a hematopoietic phenotype consistent with a hematopoietic
stem cell (HSC) defect46, but Brg1Mx1-Cre/Brm-/- double mutants did not show this
phenotype. Unlike the Snf5Mx1-Cre mutants, we observed normal hematopoietic cellularity
within bone marrow in H&E-stained femur sections from Brg1Mx1-Cre/Brm-/- double
mutants (Online Figure IX). We also performed flow cytometry and observed normal
numbers of hematopoietic stem cells, common myeloid progenitors, and common lymphoid
progenitors (data not shown). This finding suggests that HSCs require SWI/SNF complexes
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but in a non-canonical manner that is dependent on SNF5 but is independent of either
catalytic subunit. It is surprising because SWI/SNF function is usually equated with the
BRG1 or BRM DNA-dependent ATPase activity that remodels nucleosomes. Essentially all
SNF5 co-purifies with SWI/SNF complexes, and it is not required for complex
stability. 47,48 Furthermore, SNF5 protects against cancer in a BRG1-dependent
manner49,50, which suggests that the mechanism of SWI/SNF action is fundamentally
different during early hematopoiesis. It is not clear how SNF5 and the other BAF subunits
contribute to SWI/SNF function at the biochemical level in cancer or during development,
but they probably do more than simply serve as scaffolding factors that stabilize complexes
or enhance canonical catalytic activity as demonstrated previously.28 These subunits are
known to participate in the recruitment and DNA binding of complexes to downstream
target genes, which is usually viewed in an ATPase-centric manner, but our results suggest
that they also have crucial biochemical activities yet to be discovered. This idea is supported
by a recent report of BAF250/ARID1 ubiquitination activity.51
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Refer to Web version on PubMed Central for supplementary material.
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Non-standard Abbreviations and Acronyms
BRG1 brahma related gene 1
BRM brahma
VEC vascular endothelial cell
Mx1 myxovirus resistance gene 1




TEM transmission electron microscopy
PECAM-1 platelet endothelial cell adhesion molecule 1
fl floxed (flanked by loxP sites)




LVEDD LV end diastolic dimension
LVESD LV end systolic dimension
LV EF ejection fraction percentage
LV Vol d LV volume in diastole
LV Vol s LV volume in systole
NO nitric oxide
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Figure 1. Rapid death of Brg1/Brm double mutants in the Mx1-Cre model following pI-pC
treatment
A,Image of gel showing the Brg1 Δfl PCR product from the following tissues. Lanes 1-3,
tail tissue from control mice that were constitutively Δfl/+ (generated using a germline Cre
driver) or fl/+; lanes 4-7, liver (Lv) and heart (Ht) tissue from untreated (-) and pI-pC treated
(+) Brg1fl/fl; Mx1-Cre+/0 mice; lane 8, no template control (NTC). B, Kaplan-Meier survival
curve of mice following administration of either pI-pC or PBS (denoted by asterisks on days
0, 2, 4, 6, and 8). Controls: Brg1fl/fl mice lacking the Mx1-Cre transgene that were treated
with pI-pC (n = 10); Brg1fl/fl mice lacking the Mx1-Cre transgene on a Brm-/- background
that were treated with pI-pC (n = 10); Brg1 conditional null homozygotes (Brg1fl/fl; Mx1-
Cre+/0) that were treated with PBS (n = 10); Brg1 conditional null homozygotes on a Brm-/-
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background that were treated with PBS (n = 10). Single mutants: Brg1 conditional null
homozygotes on a wild-type (n = 15) or Brm+/- (n = 10) background that were treated with
pI-pC. Double mutants: Brg1 conditional null homozygotes on a Brm-/- background that
were treated with pI-pC (n = 15).
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Figure 2. Histopathologic and 2D echocardiographic findings in Brg1/Brm double-mutant hearts
Representative images of H&E-stained heart sections from a control (A) and double-mutant
(B) mice 25 days following pI-pC treatment. Animal numbers are indicated. The double-
mutant hearts have diffuse and focal interstitial hemorrhage associated with myocyte
necrosis (arrows) and calcification (arrow heads), particularly in the outer myocardium,
which may result in myocardial dissection (panel C). *, artifactual disruption of ventricular
wall due to fixative perfusion needle insertion. (C) Images extracted from 2D video
outlining the anterior wall (top) and posterior wall (bottom) cardiac dissections identified
after pI-pC treatment (see Online Table 1). The 2D video files are included (indicated in 2D
image itself) in the supplemental data section. LA=left atria; *=area of dissection on day
before death. 56% of mice had detectable dissections on mean day 38.8±9.9 (detailed in
Online Table I).
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Figure 3. M-mode echocardiographic analysis of Brg1/Brm double-mutant mice
A,Quantitative measurements of controls and double mutants. Baseline values were taken
one day after the final pI-pC treatment. Pre-mortem values were acquired one day before
double mutants died or at an equivalent time point for controls. A one-way ANOVA was
performed followed by a Holm-Sidak pair-wise comparison to determine significance
between groups, *p<0.001, **p<0.03, ***p<0.01; n.s., not significant. B, M-mode cardiac
phenotype of controls and double mutants at baseline and pre-mortem. The asterisks denote
intracardiac fluid associated with ventricular dissection.
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Figure 4. Expression analysis of BRG1, Mx1-Cre, and PECAM-1 in control and Brg1/Brm
double-mutant cardiac VECs
(A) IHC demonstrating nuclear BRG1 staining in VECs (black arrow) and cardiomyocytes
(white arrow) from a control mouse heart. (B) X-Gal staining of a representative heart
section from pI-pC-treated R26R mice carrying the Mx1-Cre transgene. Strong staining
(blue) occurred in VECs such as those enclosed by dashed circle, but staining was absent in
cardiomyocytes as exemplified by the arrows. (C) No X-Gal staining occurred in heart
sections from the same R26R mice carrying the Mx1-Cre transgene when they were not
treated with pI-pC. (D, E) IHC demonstrating PECAM-1 staining of VECs in heart sections
from control (D) and Brg1/Brm double-mutant (E) mice. A continuous staining of VECs
was observed within control vessels (D), whereas staining was discontinuous in double
mutant vessels (E).
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Figure 5. Ultrastructural defects in Brg1/Brm double mutants
Transmission electron microscopic analysis of cardiac endothelial cells demonstrates two
general defects in many of the capillary vessel walls 25 days after the first pI-pC treatment
in animal #2245. (A & B) Dying endothelial cells are present in the capillaries of treated
Brg1/Brm double mutant mice (see *). Throughout the cardiac capillary bed, gap junctions
between endothelial cells were intact between healthy cells as well as between affected cells.
Note that even between viable and injured cells the gap junctions are intact (see ‡). (C)
Vascular endothelial cells from treated Brg1/Brm double-mutant mice have swollen
mitochondria (white †) and rough endoplasmic reticulum (black †), which are characteristic
changes found in cell death. Panels A and C correspond to the epicardium, while panel B
corresponds to the endocardium.
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Figure 6. Changes in VECs occur as early as 14 days after the first pI-pC treatment of Brg1/Brm
double-mutant mice
TEM analysis of cardiac endothelial cells demonstrates the vesicular changes and the non-
uniform increase in VEC thickness in Brg1/Brm double-mutant mice 14 days after the first
pI-pC treatment (B-D), which are pronounced compared to control mice (A). Dying
endothelial cells were not found in cardiac VECs as they were at day 25. Examples of
vesicles of increased size (†) are found in most capillary sections. Data are from animals
2516 (A) and 2520 (B-D). All panels correspond to the epicardium.
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Figure 7. BRG1/BRM are required for VEC survival
A, Numbers of primary VECs from ex vivo cultures on days 7 and 14 relative to the first pI-
pC treatment (day 0). B, Levels of BrdU incorporation (left), annexin V (center), and
propidium iodide (PI, right) in VECs 7 days after first pI-pC treatment. Values are
normalized to μg DNA and presented relative to untreated non-Tg controls for each assay.
C, Permeability of VECs 1 and 7 days after the first pI-pC treatment relative to untreated
non-Tg controls. D, RT-qPCR analysis of Cd44 and Pitx2 mRNA levels normalized to
Gapdh levels in VECs at day 7. For each panel, the results are presented as mean ± SE from
3 independent experiments with significant differences indicated (*p<0.01; **p<0.001).
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